Developer docs
API playgroundTry for free, no card

Search company profiles

J.W. CHILDS ASSOCIATES, L.P.

Full company profile

uuid0009c6u

Namestring
J.W. CHILDS ASSOCIATES, L.P.
Legal namestring
J.W. Childs Associates, FL L.P.
Websiteurl
jwchilds.com
Company typeenum
Private
Founded yearint
1995
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, private equity firm, biotechnology investments, pharmaceutical investments, healthcare venture capital
Industry1 code
1Family Office Investment Platforms & Direct Investing (PE/VC/Co-Invest)
CodeFSAAADAHPrimaryYes
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • All Other Financial Investment Activities52399
SIC code2 codes
  • Investment Advice6282
  • Investors, Nec6799
Product category
Venture Capital and Private Equity Investment Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns
TypeLicensing Royalties
Description

Returns generated through equity stakes in portfolio companies. The firm builds significant equity positions as early investors and plays an active role in company development, with the goal of realizing gains through exits.

jwchilds.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

J.W. Childs Associates is a private equity and venture capital investment firm that deploys capital through direct equity investments in companies, co-investments alongside external managers, and fund investments in partner managers. It focuses on Series A and early-round investments in clinical-stage biotechnology, pharmaceutical, and healthcare consumer product companies addressing large unmet medical needs. The firm seeks to build significant equity stakes and play an active role in portfolio company development through board participation and strategic guidance.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

J.W. Childs Associates, FL L.P. is a 31-year-old private equity and venture capital investment firm that today focuses on venture capital investments in biotechnology, pharmaceuticals, and healthcare consumer products. The firm offers investment services through direct investments in companies, co-investments alongside external managers, and investments in the funds of investment managers regarded as partners. Their portfolio includes clinical-stage companies such as VeraDermics Inc. (dermatology/hair loss treatment), Biohaven Ltd. (neurosciences/immunology), Garuda Therapeutics (stem cells), and Osmol Therapeutics (neurosciences).

Product and service1 record
1Venture Capital and Private Equity Investment Services
CategoryVenture capital and private equity investment
Description

Direct venture capital and private equity investments in clinical-stage biotechnology, pharmaceutical, and healthcare consumer product companies, typically as Series A or early-round investors building significant equity stakes and playing active roles via board participation; plus co-investments alongside external managers and fund-of-fund investments in partner managers. Target audience is clinical-stage life sciences companies and healthcare consumer product companies seeking equity capital and strategic guidance.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Versant Ventures
TypeDirect peer
Description

Healthcare-focused venture capital firm investing across biotech, medical devices, and healthcare services. Comparable for early-stage clinical asset investing with active company-building involvement.

2RA Capital Management
TypeDirect peer
Description

Healthcare-focused investment firm combining public and private biotech investing with dedicated crossover and venture funds. Comparable for early-stage biotech investing and active board participation.

35AM Ventures
TypeDirect peer
Description

Early-stage venture capital firm focused on life sciences, including biotech and platform technologies. Comparable as a smaller, science-driven biotech VC investing at Series A and earlier stages.

4Frazier Healthcare Partners
TypeDirect peer
Description

Healthcare-dedicated investment firm investing across biopharma, medtech, and healthcare services at multiple stages. Comparable as a long-tenured, healthcare-specialized PE/VC with active portfolio development.

5Blackstone Life Sciences
TypeBroad incumbent
Description

Large, broad private equity platform with a dedicated life sciences franchise backing clinical-stage therapeutics and healthcare companies. Comparable as a much larger healthcare investor with overlapping therapeutic focus.

6Atlas Venture
TypeDirect peer
Description

Early-stage biotech venture capital firm that builds and funds breakthrough therapeutics, often from inception. Comparable as a Series A-focused biotech VC investing in clinical assets in large unmet-need markets.

7SR One (GlaxoSmithKline)
TypeDirect peer
Description

Healthcare and biotech venture capital firm investing in early-stage therapeutics companies. Comparable as a biotech-focused VC with significant equity positions and active development support.

8Perceptive Advisors
TypeDirect peer
Description

Healthcare-focused investment firm with both public and private strategies across biotech, medtech, and healthcare services. Comparable for early-stage biotech venture investing alongside a broader life-sciences platform.

9OrbiMed Advisors
TypeDirect peer
Description

One of the largest dedicated healthcare/biotech investment firms, making direct venture and growth investments in biopharmaceuticals, medical devices, and diagnostics. Directly comparable as a life-sciences-focused PE/VC with a multi-strategy platform.

10New Leaf Venture Partners
TypeDirect peer
Description

Healthcare-focused venture capital firm investing in clinical-stage biopharmaceutical and medical device companies. Comparable for therapeutic-area focus and active board involvement.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

J.W. CHILDS ASSOCIATES, L.P.

Venture Capital and Private Equity Investment Servicesjwchilds.com

J.W. CHILDS ASSOCIATES, L.P. firmographics

Firmographics
Name
J.W. CHILDS ASSOCIATES, L.P.
Legal name
J.W. Childs Associates, FL L.P.
Website
https://jwchilds.com
Company type
Private
Founded year
1995
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

J.W. CHILDS ASSOCIATES, L.P. industry classification

Industry
Product category
Venture Capital and Private Equity Investment Services
NAICS
Portfolio Management and Investment Advice (523940), All Other Financial Investment Activities (52399)
SIC
Investment Advice (6282), Investors, Nec (6799)
akta.pro primary industry
Family Office Investment Platforms & Direct Investing (PE/VC/Co-Invest) (FSAAADAH)

Keywords

  • Venture capital investing
  • Private equity firm
  • Biotechnology investments
  • Pharmaceutical investments
  • Healthcare venture capital

Where J.W. CHILDS ASSOCIATES, L.P. is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

J.W. CHILDS ASSOCIATES, L.P. business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Investment Returns: Returns generated through equity stakes in portfolio companies. The firm builds significant equity positions as early investors and plays an active role in company development, with the goal of realizing gains through exits.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

J.W. CHILDS ASSOCIATES, L.P. product offering

Product offering

Core offering

J.W. Childs Associates is a private equity and venture capital investment firm that deploys capital through direct equity investments in companies, co-investments alongside external managers, and fund investments in partner managers. It focuses on Series A and early-round investments in clinical-stage biotechnology, pharmaceutical, and healthcare consumer product companies addressing large unmet medical needs. The firm seeks to build significant equity stakes and play an active role in portfolio company development through board participation and strategic guidance.

Product overview

J.W. Childs Associates, FL L.P. is a 31-year-old private equity and venture capital investment firm that today focuses on venture capital investments in biotechnology, pharmaceuticals, and healthcare consumer products. The firm offers investment services through direct investments in companies, co-investments alongside external managers, and investments in the funds of investment managers regarded as partners. Their portfolio includes clinical-stage companies such as VeraDermics Inc. (dermatology/hair loss treatment), Biohaven Ltd. (neurosciences/immunology), Garuda Therapeutics (stem cells), and Osmol Therapeutics (neurosciences).

Differentiator

Problem solved

Functional benefit

Products and services

  • Venture Capital and Private Equity Investment Services Direct venture capital and private equity investments in clinical-stage biotechnology, pharmaceutical, and healthcare consumer product companies, typically as Series A or early-round investors building significant equity stakes and playing active roles via board participation; plus co-investments alongside external managers and fund-of-fund investments in partner managers. Target audience is clinical-stage life sciences companies and healthcare consumer product companies seeking equity capital and strategic guidance.

Companies that use J.W. CHILDS ASSOCIATES, L.P.

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

J.W. CHILDS ASSOCIATES, L.P. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

J.W. CHILDS ASSOCIATES, L.P. partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

J.W. CHILDS ASSOCIATES, L.P. competitors and assessment

Company assessment

Direct peers

  • Versant Ventures: Healthcare-focused venture capital firm investing across biotech, medical devices, and healthcare services. Comparable for early-stage clinical asset investing with active company-building involvement.
  • RA Capital Management: Healthcare-focused investment firm combining public and private biotech investing with dedicated crossover and venture funds. Comparable for early-stage biotech investing and active board participation.
  • 5AM Ventures: Early-stage venture capital firm focused on life sciences, including biotech and platform technologies. Comparable as a smaller, science-driven biotech VC investing at Series A and earlier stages.
  • Frazier Healthcare Partners: Healthcare-dedicated investment firm investing across biopharma, medtech, and healthcare services at multiple stages. Comparable as a long-tenured, healthcare-specialized PE/VC with active portfolio development.
  • Atlas Venture: Early-stage biotech venture capital firm that builds and funds breakthrough therapeutics, often from inception. Comparable as a Series A-focused biotech VC investing in clinical assets in large unmet-need markets.
  • SR One (GlaxoSmithKline): Healthcare and biotech venture capital firm investing in early-stage therapeutics companies. Comparable as a biotech-focused VC with significant equity positions and active development support.
  • Perceptive Advisors: Healthcare-focused investment firm with both public and private strategies across biotech, medtech, and healthcare services. Comparable for early-stage biotech venture investing alongside a broader life-sciences platform.
  • OrbiMed Advisors: One of the largest dedicated healthcare/biotech investment firms, making direct venture and growth investments in biopharmaceuticals, medical devices, and diagnostics. Directly comparable as a life-sciences-focused PE/VC with a multi-strategy platform.
  • New Leaf Venture Partners: Healthcare-focused venture capital firm investing in clinical-stage biopharmaceutical and medical device companies. Comparable for therapeutic-area focus and active board involvement.

Broad incumbents

  • Blackstone Life Sciences: Large, broad private equity platform with a dedicated life sciences franchise backing clinical-stage therapeutics and healthcare companies. Comparable as a much larger healthcare investor with overlapping therapeutic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

J.W. CHILDS ASSOCIATES, L.P. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

J.W. CHILDS ASSOCIATES, L.P. leadership team

Management profile

Number of profiles

Profiles2 records

J.W. CHILDS ASSOCIATES, L.P. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

J.W. CHILDS ASSOCIATES, L.P. M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about J.W. CHILDS ASSOCIATES, L.P.

What does J.W. CHILDS ASSOCIATES, L.P. do?

J.W. Childs Associates is a private equity and venture capital investment firm that deploys capital through direct equity investments in companies, co-investments alongside external managers, and fund investments in partner managers. It focuses on Series A and early-round investments in clinical-stage biotechnology, pharmaceutical, and healthcare consumer product companies addressing large unmet medical needs. The firm seeks to build significant equity stakes and play an active role in portfolio company development through board participation and strategic guidance.

Is J.W. CHILDS ASSOCIATES, L.P. a public or private company?

J.W. CHILDS ASSOCIATES, L.P. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was J.W. CHILDS ASSOCIATES, L.P. founded?

J.W. CHILDS ASSOCIATES, L.P. was founded in 1995. It employs 11 to 50 people.

Where is J.W. CHILDS ASSOCIATES, L.P. based?

J.W. CHILDS ASSOCIATES, L.P. is headquartered in Boston, United States, in the North America region.

How does J.W. CHILDS ASSOCIATES, L.P. make money?

One revenue line is on record: investment Returns.

Who are J.W. CHILDS ASSOCIATES, L.P.'s main competitors?

Direct peers on record are Versant Ventures, RA Capital Management, 5AM Ventures, Frazier Healthcare Partners, Atlas Venture, SR One (GlaxoSmithKline), Perceptive Advisors, OrbiMed Advisors and New Leaf Venture Partners. Blackstone Life Sciences is listed as a broad incumbent.

Does J.W. CHILDS ASSOCIATES, L.P. have an API?

No public API is recorded for J.W. CHILDS ASSOCIATES, L.P..

What industry is J.W. CHILDS ASSOCIATES, L.P. in?

J.W. CHILDS ASSOCIATES, L.P.'s product category is Venture Capital and Private Equity Investment Services. Its primary akta.pro industry code is FSAAADAH, Family Office Investment Platforms & Direct Investing (PE/VC/Co-Invest). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ForbesThis Startup Raised $20.7 Million To Develop A Kid-Friendly Wart TreatmentVeraDermics, a Connecticut-based startup founded by dermatologists, has raised $20.7 million in Series A funding to advance its kid-friendly dissolvable microneedle patch for treating common warts. The company plans to use the capital to move from pre-clinical development to randomized controlled trials to evaluate the treatment's safety and efficacy. Investors including J.W. Childs Associates and Connecticut Innovations supported the round as the firm aims to expand its pipeline into broader dermatological conditions.SecPress ReleaseBrookstone, Inc. has completed its merger with a private investment consortium led by OSIM International, resulting in the company becoming privately held and delisting from NASDAQ. Under the terms of the transaction, each outstanding share of Brookstone common stock was converted into the right to receive $20.00 in cash. The consortium also includes JW Childs Associates, LP and Temasek Holdings.PR NewswireBrynwood Partners VII L.P. Agrees to Acquire Sunny Delight Beverages Co. from J.W. Childs AssociatesBrynwood Partners VII L.P. has signed a definitive purchase agreement to acquire Sunny Delight Beverages Co. from Winter Street Opportunities Fund (managed by J.W. Childs Associates) for an undisclosed price, with the transaction expected to close in Q1 2016 pending regulatory approval. Sunny Delight is a Cincinnati-based national beverage company with over $400 million in gross sales, four U.S. manufacturing facilities, and brands including Sunny Delight, Fruit 2 O, and Veryfine, employing approximately 480 people. The acquisition represents Brynwood VII's second operating platform in the beverage sector and marks J.W. Childs Associates' exit following its 2004 acquisition of the brand from The Procter & Gamble Company.GlobeNewswireEsselte Applies for De-ListingEsselte AB applied to de-list from Stockholm, UKLA, and London Stock Exchange, effective August 1, 2002, with final trading day July 31, 2002. J.W. Childs Acquisition Sweden AB, owner of over 90% of shares, will redeem remaining shares.